MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/po.23.00425

Медицинская библиотека · JCO precision oncology · 2024

Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations.

Takeda Hiroyuki, Yamamoto Hiroyuki, Oikawa Ritsuko, Umemoto Kumiko, Arai Hiroyuki, Mizukami Takuro, Ogawa Kazuki, Uchida Yoshiyasu, Nagata Yusuke, Kubota Yohei, Doi Ayako, Horie Yoshiki, Ogura Takashi, Izawa Naoki, Moore Jay A, Sokol Ethan S, Sunakawa Yu

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Panel-based comprehensive genomic profiling (CGP) is used in clinical practice worldwide; however, large real-world data (RWD) of patients with advanced small intestine cancer have not been characterized. We investigated differences in the prevalence of clinically relevant alterations across molecularly defined or age-stratified subgroups.

PATIENTS AND

METHODS

This was a collaborative biomarker study of RWD from CGP testing (Foundation Medicine, Inc). Hybrid capture was conducted on at least 324 cancer-related genes and select introns from up to 31 genes frequently rearranged in cancer. Overall, 1,364 patients with advanced small intestine cancer were available for analyses and were stratified by age (≥40 years/<40 years), microsatellite instability (MSI) status, tumor mutational burden (TMB) status (high ≥10/low <10 Muts/Mb), and select gene alterations. The frequency of alterations was analyzed using a chi-square test with Yate's correction.

RESULTS

Genes with frequent alterations included TP53 (59.8%), KRAS (54.8%), APC (27.7%), and CDKN2A (22.4%). Frequent genes with amplifications were MYC (6.7%), MDM2 (5.9%), GATA6 (5.5%), and CCND1 (3.4%). Patients younger than 40 years had significantly lower frequency of APC mutations than those 40 years and older (10.4% v 28.7%; P = .0008). Druggable genomic alterations were detected in 22.3% of patients: BRAF V600E (1.2%), BRCA1 (1.8%), BRCA2 (3.2%), ERBB2 amplification (3.2%), KRAS G12C (3.3%), NTRK1/2/3 fusion (0.07%), MSI-high (7.0%), and TMB-high (12.2%), with no significant differences in the frequency according to age (<40 years v ≥40 years; 22.1% v 22.3%). TMB of 10-20 Mut/Mb was observed in 4.8% of patients, and TMB ≥20 Mut/Mb was seen in 7.3% of the cohort.

CONCLUSION

RWD from clinical panel testing revealed the genomic landscape in small intestine cancer by subgroup. These findings provide insights for the future development of treatments in advanced small intestine cancer.

Для цитирования: Takeda Hiroyuki, Yamamoto Hiroyuki, Oikawa Ritsuko, Umemoto Kumiko, Arai Hiroyuki, Mizukami Takuro, Ogawa Kazuki, Uchida Yoshiyasu, Nagata Yusuke, Kubota Yohei, Doi Ayako, Horie Yoshiki, Ogura Takashi, Izawa Naoki, Moore Jay A, Sokol Ethan S, Sunakawa Yu. Genomic Profiling of Small Intestine Cancers From a Real-World Data Set Identifies Subgroups With Actionable Alterations.. JCO precision oncology. 2024. DOI: 10.1200/po.23.00425.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.